Earnings call transcript: Nanosonics shares drop 14% after FY26 results

Nanosonics reported FY26 revenue of AUD 203.9M (+3% reported / +6% constant currency) and EBIT of AUD 16.0M (+21% constant currency), with trophon placements up 9% to 4,230 units. Despite this, shares fell 14.4% to $3.15 as FY27 guidance implies margin moderation (gross margin to 74%-76% vs 76.9%) and higher spending for the CORIS launch, with FY27 constant-currency revenue guided to AUD 220M–228M (+8% to +12%). Management flagged tariff pressure (12.5% expected U.S. tariff rate), higher freight costs, and a deliberate investment step-up concentrated in FY27.

Analysis

The selloff looks more like a margin-quality reset than a demand thesis break. The core franchise is still throwing off enough cash to fund the launch, which matters because it reduces dilution risk and gives management room to execute without stressing the balance sheet; that usually limits downside versus other pre-commercial medtech stories. The market is probably discounting FY27 as an earnings trough, but that can reverse quickly if trophon3 mix and upgrade conversion keep improving into the next two quarters.

The more interesting second-order effect is competitive capture of service economics, not just device placements. As the installed base modernizes, the company keeps pulling annuity revenue back from the incumbent service provider, and that can quietly improve mix for years even if top-line growth looks modest. For GEHC, the pressure is less about direct revenue loss and more about being displaced from the embedded service relationship that historically sat around the legacy fleet.

Risk is execution, not capital. The key near-term catalyst is whether the second U.S. regulatory step clears on schedule and whether early CORIS commercial activity converts from pilot interest into actual installed units; if either slips, the market will keep treating CORIS as option value with a high discount rate. Falsifiers are simple: sustained gross margin below the low end of guidance, a material delay in U.S. launch timing, or evidence that consumables growth was a weather bounce rather than a durable step-up.

Contrarian take: consensus may be overemphasizing the FY27 opex step-up and underweighting the free call option created by a debt-free balance sheet plus buybacks. If CORIS only works modestly, the stock can still re-rate on cleaner core execution; if it works, the current valuation likely understates the long-dated annuity economics. This is a better ‘show me’ setup than a ‘believe me’ setup, so position size should reflect launch risk.

Key Decisions for Investors

• Tactically buy NNCSF/TSNLF on post-earnings weakness for a 1-3 month trade; risk/reward improves if the stock holds near the lower end of its 52-week range and management reiterates FY27 launch timing. Stop if the second FDA review slips or FY27 gross margin guidance moves below 74%.
• Pair trade: long NNCSF/TSNLF vs short GEHC over 6-12 months to express the thesis that upgrade-driven installed-base migration captures recurring service economics away from the incumbent. Cover the short if GEHC’s service mix inflects unexpectedly or if Nanosonics’ upgrade cadence slows materially.
• Set an alert on CORIS commercialization milestones rather than buying optionality via calls today; the cleaner entry is after the first tangible evidence of paid installations, not before. This is the better risk/reward point because launch-year revenue is likely too small to support a re-rate on its own.
• If already long, trim only on a failed launch signal, not on the FY27 expense guide alone; the guide mostly compresses near-term EPS, while the structural value is in FY28+ annuity expansion.